Abstract 2318P
Background
Molecular techniques have improved cancer diagnosis and treatment. Due to limited availability and costs, broad molecular profiling, i.e., analysis of whole genomes/exomes, transcriptomes, and methylomes, is rarely performed upfront in clinical practice and mostly confined to research settings. However, in contrast to more readily available focussed analyses of, e.g., the few genes seemingly relevant for a suspected diagnosis, broad molecular profiling may yield unsuspected findings pertinent to diagnosis and/or treatment.
Methods
This analysis is based on patients enrolled in the MASTER program of DKFZ, NCT Heidelberg/Dresden, and DKTK, a nationwide precision oncology network applying genome/exome, transcriptome, methylome, and – more recently – proteome analysis in young adults with advanced malignancies and patients with rare cancers to inform clinical decision-making and the design of molecularly stratified clinical trials. Cases with molecular findings suggestive of an alternative diagnosis are subjected to clinical, molecular, and pathologic revaluation.
Results
In 99 of 3,092 patients (3.2%), the molecular profile warranted revaluation of the clinical diagnosis. The most frequent presenting diagnoses were cancer of unknown primary (n=21); various sarcomas (n=50), e.g., sarcoma not otherwise specified (n=4), malignant peripheral nerve sheath tumor (n=5), and undifferentiated sarcoma (n=6); and melanoma (n=4). Molecular findings suggesting an alternative diagnosis were based on genome/exome, transcriptome, and methylome analysis in 30, 78, and 41 cases, respectively. Potential clinical consequences were classified as changes in diagnosis without relevance for treatment (n=22), relevant for routine treatment (n=58), and prompting molecular alteration-specific treatment (n=19). The molecularly suspected diagnosis was confirmed in a major subset of cases for which sufficient material for histopathologic review was available. The clinically most relevant findings were EWSR1::WT1 fusions and diagnosis of desmoplastic small round cell tumor (n=9) and druggable gene fusions involving FGFR2 (n=4), ALK (n=4), and NTRK3 (n=1).
Conclusions
Broad molecular profiling is a useful adjunct to routine cancer diagnostics, especially in rare entities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
DKFZ.
Funding
NCT Molecular Precision Oncology Program, German Cancer Consortium.
Disclosure
C.E. Heilig: Financial Interests, Institutional, Funding: AstraZeneca, Pfizer, PharmaMar, Roche. S. Bauer: Financial Interests, Institutional, Research Funding: Blueprint Medicines, Incyte, Novartis; Financial Interests, Personal, Other, Honoraria: PharmaMar, Eli Lilly & Co, Novartis; Financial Interests, Personal, Advisory Board: Adcendo, Bayer, Blueprint Medicines, Boehringer Ingelheim, Cogant, Daiichi Sankyo, Deciphera, GSK, Exelixis, Nanobiotix, Novartis, Roche; Financial Interests, Personal, Other, travel support: PharmaMar. D.T. Rieke: Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Other, Honoraria: Lilly, BMS, Roche, Bayer; Financial Interests, Personal, Other, Travel or accommodation expenses: Bayer. P. Horak: Financial Interests, Personal, Advisory Board: Platomics; Financial Interests, Personal, Other, Consulting: Platomics; Financial Interests, Personal, Other, Honoraria: Platomics, Roche, Trillium. S. Fröhling: Financial Interests, Personal, Advisory Board: Bayer, Illumina, Roche; Financial Interests, Personal, Invited Speaker: Amgen, Eli Lilly, Illumina, PharmaMar, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
2273P - Influence of body mass index (BMI) on the response to chemotherapy in patients with HER2+ breast cancer: Role of the leptin axis
Presenter: Marta González Rodríguez
Session: Poster session 08
2274P - Deep learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study
Presenter: Christian Esposito
Session: Poster session 08
2275P - Circulating leptin and adiponectin levels in premenopausal women with and without breast cancer (BC) and a body mass index (BMI) ≥25 kg/m2
Presenter: Isabel Calvo
Session: Poster session 08
2276P - Regulation of major histocompatibility class-I gene methylation using DNA methyltransferase inhibitor and PD-L1 inhibitor in triple-negative breast cancer
Presenter: Young Ju Jeong
Session: Poster session 08
2277P - A colorimetric biosensor to track Trop-2 status of tumor cells for diagnosis of breast cancer
Presenter: Tianyu Zeng
Session: Poster session 08
2278P - Endothelial cell heterogeneity defined by single-cell spatial transcriptomic analysis of breast cancers
Presenter: Krisztian Homicsko
Session: Poster session 08
2279P - Glucocorticoid receptor antagonism and beta adrenergic receptor inhibition: Implications in triple-negative breast cancer brain metastasis
Presenter: Andra Antohi
Session: Poster session 08
2280P - MiR-193a-3p: A pan-repressor of H2S synthesizing enzymes regulates tumorigenesis and immunosurveillance in breast cancer
Presenter: Alyaa Dawoud
Session: Poster session 08
2281P - Multi-omics evaluation of TFE3-fusions and potential association with immuno-metabolic vulnerabilities in alveolar soft part sarcoma (ASPS) and translocation-positive renal cell carcinoma (tRCC)
Presenter: Shuanzeng Wei
Session: Poster session 08
2282P - Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma
Presenter: Qin Jian Low
Session: Poster session 08